A CML Patient Carrying <i>BCR::ABL1</i> Splicing Variants Did not Experience Blast Crisis for 15 Years without Responding to Various TKIs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A CML Patient Carrying <i>BCR::ABL1</i> Splicing Variants Did not Experience Blast Crisis for 15 Years without Responding to Various TKIs

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Nakamura Fumi¹,Sasaki Ko¹,Nannya Yasuhito²³,Iso Hisako¹,Nakamura Yuko¹,Imai Yoichi¹,Ogawa Seishi²⁴,Mitani Kinuko¹

Affiliation:

1. Department of Hematology and Oncology, Dokkyo Medical University, Japan

2. Department of Pathology and Tumor Biology, Kyoto University, Japan

3. Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Japan

4. Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_4163-24/_pdf

Reference21 articles.

1. 1. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 34: 2333-2340, 2016.

2. 2. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30: 1044-1054, 2016.

3. 3. Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. Cancers 14: 3300, 2022.

4. 4. Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MWN, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 38: 10-20, 2014.

5. 5. Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369: 1783-1796, 2013.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3